Molecular biology sales are boosting Biomérieux revenues

Biomerieux reported that its third quarter revenues rose 7 percent from Q3 2015, including a 46 percent jump in molecular biology sales. For the quarter ended Sept. 30, the company reported total revenues of €510.8 million ($557.3 million) from €478.3 million a year ago. There was a nearly 2 percent increase in sales related to subsidiary BioFire Defense.

Revenues from clinical applications, meanwhile, were up more than 8 percent in the third quarter to €405.6 million. This was largely due to a 46 percent increase in revenues from the molecular biology subcategory, which grew to €73.5 million in the quarter from €50.3 million in Q3 of 2015. The firm noted that expansion in installations of the BioFire FilmArray system — to an installed base of almost 3,500 units — and the success of the firm’s gastrointestinal panel, helped boost sales in the FilmArray line.

During Q3, Biomerieux also received clearance from the Chinese Food and Drug Administration for its FilmArray 2.0 system, and panels are still being reviewed by local authorities there. Its BioFire affiliate was granted CLIA waiver for the FilmArray Respiratory Panel to be used outside of a laboratory setting, and commercial launch is expected in November.